Volume 43, December 2008 T he American Society of Health-System Pharmacists (ASHP) issued a press release in September 2008 stating that they were launching a collaborative initiative with the Foundation for Evidence-Based Medicine (FEBM) to evaluate and publish evidence related to "off-label" uses of medications. This information will be incorporated into the drug monographs published as supplements to ASHP's drug compendium, AHFS Drug Information, and posted on www.ahfsdruginformation.com. The initial focus of this collaborative effort will be new uses of cancer drugs. [1] [2] [3] Off-label prescribing has been described by Dr. Randall S. Stafford in his editorial on regulating offlabel drug use and rethinking the role of the US Food and Drug Administration (FDA) as …the prescription of a medication in a manner different from that approved by the FDA.
[It] is legal and common, [and] it is often done in the absence of adequate supporting data. Off-label uses have not been formally evaluated, and evidence provided for one clinical situation may not apply to others. 4 The extent to which drugs are prescribed for off-label use is great and varies with the type of drug. An evaluation of the IMS National Disease and Therapeutic Index data from 2001 found that 21% of the sample drugs were prescribed for off-label use. 5 In 2003, it was estimated that off-label use ac counted for three-quarters of some antiseizure prescriptions, two-thirds of some antipsychotic prescriptions, and one-quarter of some antidepressant prescriptions. 6 Furthermore, the rate of off-label use is perhaps even higher among prescriptions for pediatric patients, 7 especially when considering that the labeling for most new drugs states that the safety and effectiveness of these drugs has not been established in children.
The previously noted quotation by Dr. Stafford regarding off-label use is fairly accurate when applied to clinical practice. The only way that the use of a drug may be classified as "on-label" is if the applicant submits a Supplemental New Drug Application to the FDA. Generally, this is done by the innovating pharmaceutical company or their partner, and it is an expensive and time-consuming process. Because prescribers are not restricted to prescribing medications only for their approved on-label use, a number of prescriptions are written for uses for which there is either an abundance of evidence or little to no published scientific data supporting those uses. 8 The Agency for Healthcare Research and Quality published their evaluation of the supportive literature for use of the various atypical antipsychotics for the treatment of dementia-related behavioral problems, depression, obsessive-compulsive personality disorder, posttraumatic stress disorder, personality disorders, and Tourette syndrome in children and adolescents in 2007. This report concluded that "with few exceptions, there is insufficient highgrade evidence to reach conclusions about the efficacy of atypical antipsychotic medications for any of the off-label indications, either vs placebo or vs active therapy." 9 ASHP and FEBM should be congratulated for this much-needed initiative, but they are not alone. Lexi-Comp, Inc., has had off-label uses within its monographs for years. 10-14 Off-Label Drug Facts has published quarterly a set of unbi-ased reviews that includes an evaluation and rating of the data, references, and suggested readings since 2001. The Drugdex System, Drug Indications Database, Clinical Pharmacology, and Lexi-Comp databases provide information on accepted off-label uses within their drug monographs.
What separates the ASHP/ FEBM initiative from these other systems is that applicants can submit a formal application to FEBM for consideration of an off-label use of a medication. The application can be obtained from FEBM at http://www.thefebm.org/about /procedures.html. The review process begins once the application, supportive information, and a related fee ($50,000) are submitted to FEBM. Then the scientific literature and data are evaluated and a report is generated that includes a rating of the strength of the evidence, the grade of the recommendation, and the disclosure of any possible conflicts of interest among the committee members. [1] [2] [3] 15 The good news for practitioners and third-party payers (eg, health plans, government programs) is that all of these resources are valuable tools in day-to-day practice and provide information that helps health care professionals make decisions relative to the off-label use of drugs. Thus the more evidence-based information these systems and databases contain, the better. With this type of initiative and resources, we all can gain more evidence-based knowledge and hopefully patient care will be improved.
